About 4E Therapeutics
4E Therapeutics is a company based in Austin (United States) founded in 2019 by Joe Price and Craig Benson was acquired by Lilly in June 2026. It operates as a HealthTech. 4E Therapeutics has raised $1.89 million across 1 funding round from investors including Lilly. 4E Therapeutics offers products and services including Neuropathic Pain Treatment, Migraine Treatment, and Acute Pain Treatment. 4E Therapeutics operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Austin, United States
- Founders Joe Price, Craig Benson
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name 4E Therapeutics Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of 4E Therapeutics
4E Therapeutics offers a comprehensive portfolio of products and services, including Neuropathic Pain Treatment, Migraine Treatment, and Acute Pain Treatment.
Innovative therapy developed for chronic neuropathic pain relief.
Compounds being researched for effective migraine pain management.
Solutions under development for managing acute pain conditions.
Funding Insights of 4E Therapeutics
4E Therapeutics has successfully raised a total of $1.89M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.89 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in 4E Therapeutics
4E Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Lilly.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Locked | Locked | Locked |
Investor details for 4E Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by 4E Therapeutics
Investment portfolio details for 4E Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - 4E Therapeutics
Detailed financials for 4E Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
4E Therapeutics Comparisons
Peer comparison for 4E Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of 4E Therapeutics
4E Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Pain treatment products are developed through reformulation technologies.
|
Detailed competitors of 4E Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on 4E Therapeutics
Complete news archive for 4E Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about 4E Therapeutics
4E Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
4E Therapeutics is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Craig Benson is the current CEO of 4E Therapeutics. They have also founded this company.
4E Therapeutics is a funded company, having raised a total of $1.89M across 1 funding round to date.
4E Therapeutics is focused on developing next-generation treatments for neuropathic pain. Based in Austin, Texas, the company targets underlying neurological mechanisms causing pain. Solutions are created for chronic neuropathic pain, migraine, and acute pain. The neuroscience sector is prioritized with a commitment to non-addictive medications. Clinical development has been initiated for cutting-edge therapies. Research and innovation are driven by a world-class team of experts.
4E Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
4E Therapeutics offers Neuropathic Pain Treatment, Migraine Treatment, and Acute Pain Treatment.
4E Therapeutics has 1 investor. Key investors include Lilly.